PS.
PublicSupply
account_balanceBuyersbusinessSuppliersdescriptionNoticescategoryCategories
BuyersSuppliersNoticesCategories
verified_userData sourced from Contracts Finder, Find a Tender, and Companies House.
Contracts Finder ↗Find a Tender ↗Procurement Act 2023 ↗
  1. Home›
  2. Suppliers›
  3. ORION PHARMA (UK) LIMITED
OP

ORION PHARMA (UK) LIMITED

London
SME

Orion Pharma (UK) Limited is involved in the pharmaceutical industry, focusing on various therapy areas such as pain management, cancer, respiratory diseases, and women's health. They also emphasize sustainability in their operations.

orionpharma.co.uk ↗

Summary from the supplier’s website — unverified

Compare peers
Awarded
£688.8m
Live
11
Buyers
4
12m
£688.8m
At a glance
  • Quick answer
Profile
  • Social value
  • ESG & policies
  • Capabilities
  • Buyer references
  • Accreditations
Track record · verified
  • KPI performance
  • Contracts11 / 12
  • Top buyers4
  • Category mix
  • Geography
  • Peers5
Trust & risk
  • Red flags0
  • Compliance
  • Modifications
  • News
Company
  • Companies House
  • Financial
  • Org tree
Quick answer — ORION PHARMA (UK) LIMITEDUpdated 20 Jul 2026

At a glance · for buyers and watchdogs

ORION PHARMA (UK) LIMITED has won £688.8m across 4 public-sector buyers, with 11 live contracts. No active Companies House risk flags.

Why: top buyer NHS England North East and Yorkshire Health and Justice at 100% · 0 active risk flags · 0 modifications.

Decision signals
0Active red flags
ActiveCompany status
11 of 12Live contracts
100%Top-buyer concentration
—Category exposure
0Contract modifications
If you're a buyer:CapabilitiesReferencesKPIComplianceWatchdog?FlagsModificationsConcentrationNews

Social value · 1/5

Commitments mapped to the Government Social Value Model themes. Each is tagged self-reported or from the website.

◐ From supplier website
JobsNo commitment stated✓
SkillsNo commitment stated✓
Environment1 commitment ↗✓
Tackling inequalityNo commitment stated✓
CommunityNo commitment stated✓
Environment · 1
  • WebsiteCarbon Footprint Assessment of Orion's Dry Powder InhalersAn assessment of the carbon footprint associated with Orion's dry powder inhalers.

Extracted automatically from orionpharma.co.uk on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

ESG & policies vault · 0/5

Key governance & sustainability policies. Published documents link out; missing ones are greyed.

↔ Cross-checked
Net-zero planNot provided✓
Modern slavery statementNot provided✓
EDI policyNot provided✓
Anti-briberyNot provided✓
Data protectionNot provided✓

Capabilities

What this supplier does, where they sit, who they sell to.

◐ From website & notices
Sectors served · 1/8
Central government✓
Local government✓
NHS & health✓
Housing✓
Utilities & energy✓
Financial services✓
Education✓
Defence✓
Services · 3
ProductsPharmaceutical products across various therapy areas. ↗Healthcare ProfessionalsResources and information for healthcare professionals. ↗SustainabilityEfforts towards sustainability and carbon footprint assessment. ↗

Extracted automatically from orionpharma.co.uk on Jul 2026. Not independently verified — treat as the supplier’s own marketing claims.

Case studies

Delivery stories the supplier has published, with sector and outcome.

⚑ Self-reported
—

No case studies yet

Once a claimed supplier publishes delivery stories — the buyer, the sector, what was delivered and the outcome — they appear here.

Buyer references

Named public-sector contacts who have agreed to act as a reference.

✓ Confirmed by buyer
—

No buyer references yet

Public-sector buyers can confirm they'll act as a reference for this supplier. Confirmed references — with the contract they relate to — show here.

Accreditations & memberships

Independently issued. Verification dates cross-checked against issuer registers.

↔ Cross-checked
—

No accreditations recorded

B-Corp, ISO, Cyber Essentials, Living Wage and similar credentials appear here once added by a claimed supplier and cross-checked against the issuing register.

KPI performance

Delivery, budget and satisfaction scores reported quarterly by buyers.

✓ Verified
84

No verified KPI scores yet

Once buyers report contract KPIs — delivery on time, on budget, satisfaction, adoption and accessibility — a weighted grade and breakdown appear here.

Contracts · 11 live · 1 historic

Pulled from Contracts Finder & Find a Tender. Most recent first.

✓ From notices
TitleBuyerCPVAwardedValueTermStatus
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS England North East and Yorkshire Health and Justice—01 Dec 2025£688.8m1.5 yrspending
NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 2)
NHS England3360000001 Jun 2024£0.023 yrsLive
Generic Drugs - Injections/Infusions
Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)————Live
Proprietary Drugs
Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)————Live
NHS National Generic Pharmaceuticals Wave 14c
NHS England33600000———Live
NHS National Generic Pharmaceuticals Wave 14b
NHS England33600000———Live
NHS National Generic Pharmaceuticals Wave 14b
NHS England33600000———Live
NHS National Framework for Medical Retinal Vascular Treatments 1 August 2024
NHS England33600000———Live
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS England————Live
Proprietary Drugs
eTenderwales————Live
Total live value £0.02 · mean award £57.4m1–10 of 12

Top buyers · 4 buyers · top 3 = 100%

Share of awarded value. Concentration fires above 40% for any single buyer.

✓ From notices
1
NHS England North East and Yorkshire Health and Justice
1 contract
100%
since 2025
2
NHS England
7 contracts
0%
since 2024
3
Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts)
3 contracts
0%
4
eTenderwales
1 contract
0%

Geography

Distribution of awarded value by buyer region.

✓ From notices
UK · schematic only
Yorkshire8 contracts
100%
Wales4 contracts
0%

Peers

Suppliers with overlapping CPVs & buyers (last 24m). ORION PHARMA (UK) LIMITED highlighted.

✓ From notices
SupplierSME?Awarded · 24mContracts
OP
ORION PHARMA (UK) LIMITED
Yes£688.8m—
DR
Dr Reddy's Laboratories (UK) Ltd
Yes£121.0m22
JA
Janssen-Cilag Ltd
Yes£117.6m18
AB
AbbVie Ltd
Yes£95.2m12
TA
Thornton and Ross Ltd
Yes£72.5m12
AC
ACCORD-UK LTD
Yes£71.2m21
Compare peers →

Red flags · 0 active

Automated scan of Companies House status, charges and insolvency records.

✓ Verified
✓ Clean. No active risk signals from Companies House status, charges or insolvency records.

Compliance scorecard

Derived from Companies House filings — not a full supplier-assurance check.

↔ Cross-checked
Trading status
Active
Live at Companies House
Annual accounts
Up to date
Last made up to 31 Dec 2024
Confirmation statement
Up to date
Next due 26 Nov 2026
Outstanding charges
0
No charges registered
Insolvency history
None
No insolvency cases registered
Certifications (ISO, Cyber Essentials, Living Wage, B-Corp, modern-slavery) are supplier self-reported and appear once a claimed profile adds them.

Modifications

Variations to awarded contracts logged under Procurement Act 2023 s.74.

✓ From notices
±

No modifications recorded

No published contract variations for this supplier. Modification notices appear here as they are issued under the Procurement Act 2023.

News mentions

UK trade press & nationals, matched to this supplier.

◰

No news mentions found

We haven't matched any recent UK press coverage to this supplier. Mentions appear here automatically as they're published.

Companies House

Live sync — registered details, directors, PSC and SIC codes.

✓ Live sync

Registered details

Company no.
02281057
Status
Active
Type
Private limited
Incorporated
27 Jul 1988
Reg. office
The Scalpel, 18th Floor, 52 Lime Street, London, EC3M 7AF
SIC codes
46460
Last accounts
31 Dec 2024
Next accounts due
30 Sept 2026

Directors & PSC

  • KEMPPAINEN, Mikko Tapani — director
    Appointed 07 Feb 2025
  • LINDELL, Rene Kristian — director
    Appointed 16 Apr 2024
  • JTC (UK) LIMITED — corporate secretary
    Appointed 23 Mar 2023
  • HURME, Aino Anna Liisa, Dr — director
    Appointed 01 Jan 2023
  • Orion Corporation — person with significant control
    ownership of shares 75 to 100 percent

Financial

Filed accounts from Companies House.

↔ From Cos House
£

No financial filings on record

Turnover, profit and headcount appear here once audited or micro-entity accounts are filed at Companies House.

Org tree

Group structure and ownership.

↔ From Cos House
ORION PHARMA (UK) LIMITED
02281057 · this company

Independent. No parent company or subsidiaries recorded at Companies House for this entity.